Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Managing NF1 PN with this First and Only FDA-Approved Treatment Option

Details
Recommended

Overview

ReachMD Image
RestartResume

Tune in to watch a leading expert in NF1 PN discuss their insights into disease management and treatment goals with KOSELUGO®  (selumetinib).

  • Sponsored by

  • Overview

    Dive in with Dr. Pinki Prasad, Pediatric Oncologist and Associate Professor in Pediatrics at LSU School of Medicine, to learn more about recommended NF1 PN testing, symptom management, and preparing caregivers and pediatric patients for the treatment journey with KOSELUGO® (selumetinib).

    NF1 = Neurofibromatosis Type 1
    PN = Plexiform Neurofibromas

  • SELECT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS associated with Koselugo (selumetinib) include Cardiomyopathy, Ocular Toxicity, Gastrointestinal Toxicity, Skin Toxicity, Increased Creatine Phosphokinase, Increased Levels of Vitamin E and Risk of Bleeding, and Embryo-Fetal Toxicity.

    ADVERSE REACTIONS (≥40%) include vomiting, rash (all), abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acneiform rash, stomatitis, headache, paronychia, and pruritus.

    DRUG INTERACTIONS include strong/moderate CYP3A4 Inhibitors or Fluconazole and CYP3A4 Inducers.

    Please see additional Important Safety Information or visit bit.ly/KoselugoPI to see accompanying full Prescribing Information for Koselugo® (selumetinib).

    KOSELUGO is a registered trademark of the AstraZeneca group of companies.
    ALEXION and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc.
    © 2024, Alexion Pharmaceuticals, Inc. All rights reserved.  US/KOS-NF1/0795 V1 06/2024

     
Schedule13 Dec 2024